Human medicines European public assessment report (EPAR): Zynlonta, loncastuximab tesirine, Date of authorisation: 20/12/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Idefirix, imlifidase, Date of authorisation: 25/08/2020, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Abrysvo, respiratory syncytial virus vaccine (bivalent, recombinant), Date of authorisation: 23/08/2023, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Fasenra, benralizumab, Date of authorisation: 08/01/2018, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Xolremdi, mavorixafor, Date of authorisation: 27/04/2026, Revision: 4, Status: Authorised

International collaboration on GMP inspections

Report on the International Active Pharmaceutical Ingredient Inspection Programme 2017 – 2024

Human medicines European public assessment report (EPAR): Aybintio, bevacizumab, Date of authorisation: 19/08/2020, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Saphnelo, anifrolumab, Date of authorisation: 14/02/2022, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Vyloy, zolbetuximab, Date of authorisation: 19/09/2024, Revision: 5, Status: Authorised